KalVista Pharmaceuticals, Inc. Common Stock (KALV)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 270
- Market Cap
- $1.4B
About KalVista Pharmaceuticals, Inc. Common Stock
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
SentiSense also tracks daily options readings for KalVista Pharmaceuticals, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
KalVista Pharmaceuticals, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.